<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03778580</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR5451</org_study_id>
    <nct_id>NCT03778580</nct_id>
  </id_info>
  <brief_title>Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine</brief_title>
  <official_title>Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes Treated With Pyridoxamine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a specific form of Vitamin B known as&#xD;
      Pyridoxamine helps improve bone strength over one year in women (&gt;65 yrs old) with Type 2&#xD;
      Diabetes. The investigators know that people with type 2 diabetes have the lower bone&#xD;
      material strength and the investigators suspect this is due to high levels of circulating&#xD;
      sugars that build up over time (known as Advanced Glycation Endproducts). The investigators&#xD;
      will study whether using a specific form of vitamin B, known as pyridoxamine helps improve&#xD;
      bone strength and reduce levels of circulating sugars over a one year time period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 Diabetes Mellitus (T2DM) has become one of the most important diseases of our time.&#xD;
      Recent research shows that diabetes has negative effects on bones and that people with&#xD;
      diabetes might more likely to break a bone. The investigators don't know the reasons for&#xD;
      this, but the investigators suspect that normal bone replacement is slowed down in diabetes&#xD;
      and this could slow down the growth of new bone. It is possible that the normal material&#xD;
      becomes weaker because sugar-related components (&quot;Advanced Glycation Endproducts&quot;) are making&#xD;
      the bone more brittle. The investigators have shown in past research that people who have&#xD;
      type 2 diabetes are more likely to have both weaker bone with lower &quot;bone material strength&quot;&#xD;
      and also higher level of sugar-related components(&quot;Advanced Glycation Endproducts&quot;). This&#xD;
      study will focus on attempting to lower the sugar-related components(&quot;Advanced Glycation&#xD;
      Endproducts&quot;) by treating a group of patients with type 2 diabetes with an over- the- counter&#xD;
      B vitamin, known as vitamin B6 or pyridoxamine for one year. The investigators will compare&#xD;
      post-menopausal women both before and after pyridoxamine use and study them in terms of&#xD;
      different bone features based on blood tests, bone imaging, a bone indentation test and a&#xD;
      measurement of sugar-related components in the skin. This study will help to clarify if using&#xD;
      pyridoxamine helps improve bone strength in women with diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone formation in serum by P1NP</measure>
    <time_frame>12 months</time_frame>
    <description>change in serum biochemical marker of bone formation, P1NP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Advanced glycation endproducts</measure>
    <time_frame>12 months</time_frame>
    <description>Skin assessment of advanced glycation endproducts</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>pyridoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>identical placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>identical placebo po bid for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Pyridoxamine Dihydrochloride</intervention_name>
    <description>pyridoxamine dihydrochloride (over- the- counter type of vitamin B6) 200 mg po bid</description>
    <arm_group_label>pyridoxamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>identical placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women ≥65 years&#xD;
&#xD;
          -  Diagnosis of T2D for ≥ 5 years, with all HbA1c levels.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hormone replacement treatment (HTR) use (to avoid the influence of estrogen).&#xD;
&#xD;
          -  Fractures (excluding skull, facial bones, metacarpals, fingers, toes, and fractures&#xD;
             associated with severe trauma) within 12 months.&#xD;
&#xD;
          -  A history of pathological fractures (eg, due to Paget's disease, myeloma, metastatic&#xD;
             malignancy).&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Disorders associated with altered skeletal structure or function (chronic liver&#xD;
             disease' chronic renal disease stage 4 [eGFR &lt; 30 mL/mim/1.73 m2] or worse,&#xD;
             malignancy, hypoparathyroidism or hyperparathyroidism,acromegaly, Cushing's syndrome,&#xD;
             hypopituitarism, alcohol intake &gt; 3U/day).&#xD;
&#xD;
          -  Treatment with any of the following drugs in part year:current corticosteroid,&#xD;
             anticonvulsant therapy(phenytoin, phenobarbital, primidone, carbamazepine), SGLT2&#xD;
             inhibitor if on it for &lt; 1 year), pharmacological doses of thyroid hormone&#xD;
             (TSH&lt;normal), adrenal or anabolic steroids, Aromatase inhibitors, calcitonin,&#xD;
             bisphosphonates, denosumab, estrogen, or selective estrogen receptor modulator, sodium&#xD;
             fluoride, teriparatide, thiazolidinediones(TZDs).&#xD;
&#xD;
          -  Serum 25(OH)D levels &lt; 20 ng/ml. If 25(OH)D levels are &lt; 20 ng/ml, rescreening will be&#xD;
             allowed following a vitamin D loading regimen of 50,000 IU/week for 4 weeks. If serum&#xD;
             25(OH) D levels are ≥ 20 ng/ml after supplementation, the subject will be allowed to&#xD;
             enroll.&#xD;
&#xD;
          -  Current use of pyridoxamine (although not multivitamin or vitamin B6 users because&#xD;
             pyridoxamine is not at pharmacologic levels in these supplements).&#xD;
&#xD;
          -  Allergy to pyridoxamine and vitamin B6.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mishaela Rubin,, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center - Harkness Pavillion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Mishaela Rubin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin B6</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyridoxamine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT03778580/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

